Daclizumab

Subcutaneous
Relapsing forms of multiple sclerosis

Contraindicated.

Pre-existing hepatic disease or hepatic impairment including ALT or AST ≥2 times the upper limit of normal (ULN), history of autoimmune hepatitis.

Patient w/ previous or current depressive disorders, severe active infection, TB. Pregnancy and lactation.

Hypersensitivity reactions e.g. anaphylaxis, angioedema, urticaria, rash, pruritus), dermatitis, eczema, psoriasis, skin exfoliation, acne, erythema, dry skin, toxic skin eruption; lymphadenopathy, lymphadenitis, non-infectious colitis; nasopharyngitis, upper resp tract infection, pneumonia, bronchitis, viral infection, influenza, laryngitis, tonsillitis, pharyngitis, folliculitis, anaemia, depression, oropharyngeal pain, diarrhoea, pyrexia, increased ALT/AST.
Potentially Fatal: Autoimmune hepatitis; hepatic failure.

Parenteral/SC: C

Monitor serum transaminases (ALT and AST) and bilirubin levels prior to initiation, monthly during treatment, and up to 4 mth after last dose.

May reduce the therapeutic effect of live vaccines.

Description:
Mechanism of Action: Daclizumab is a humanised monoclonal antibody that blocks interleukin-2 (IL-2) receptor by binding to the α-chain (CD25 subunit) on the surface of activated T-lymphocytes. The precise mechanism by which it exerts therapeutic effects in multiple sclerosis is unknown.
Pharmacokinetics:
Absorption: Bioavailability: Approx 90%. Time to peak plasma concentration: 5-7 days.
Distribution: Primarily confined to vascular and interstitial spaces; crosses placenta. Volume of distribution: Approx 6.34 L.
Metabolism: Catabolised to peptides and amino acids.
Excretion: Terminal elimination half-life: Approx 21 days.

Store between 2-8°C. Protect from light. Do not freeze.

Immunosuppressants

L04AC01 - daclizumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.

Anon. Daclizumab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 28/09/2016.

Buckingham R (ed). Daclizumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 28/09/2016.

Zinbryta Injection, Solution (Abbvie). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 28/09/2016.